NERLYNX®

Hold Company

PUMA BIOTECH

Learn More

Dosage and Administration

TABLET;ORAL

Specification

EQ 40MG BASE

Indication

NERLYNX® is suitable for the expansion of early breast cancer adjuvant therapy, as well as advanced or metastatic breast cancer.

Use

Instructions for Use

API

NERATINIB MALEATE

API Structure

We Supply

NERATINIB MALEATE

Note:

null

null

Note:

null

null

Note:

null

Drug Patent

Patent No	Expiration Date
10035788	2028/10/15
7399865	2030/12/29
7982043	2025/10/8
8518446	2030/11/20
8669273	2031/7/18
8790708	2030/11/5
9139558	2028/10/15
9211291	2030/3/24
9265784	2029/8/4
9630946	2028/10/15

API Patent

Patent No	Expiration Date
7399865	2030/12/29
7982043	2025/10/8

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.